Here, we therapeutically exploited the myeloid-driven pro-tumorigenic effects orchestrated by GM-CSF to rewire the NrasG12D TME into sustaining cancer cell survival and proliferation, a process further hindered upon combination with the clinically-approved VEGF inhibition, which led to increased tumor necrosis. The gene discussed is CSF2; the disease is cancer.